Review



rabbit anti occludin polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech rabbit anti occludin polyclonal antibody
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Anti Occludin Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1279 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti occludin polyclonal antibody/product/Proteintech
    Average 96 stars, based on 1279 article reviews
    rabbit anti occludin polyclonal antibody - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Chitosan alleviates symptoms of Parkinson’s disease by reducing acetate levels, which decreases inflammation and promotes repair of the intestinal barrier and blood–brain barrier"

    Article Title: Chitosan alleviates symptoms of Parkinson’s disease by reducing acetate levels, which decreases inflammation and promotes repair of the intestinal barrier and blood–brain barrier

    Journal: Neural Regeneration Research

    doi: 10.4103/NRR.NRR-D-23-01511

    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and occludin expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Figure Legend Snippet: Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and occludin expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.

    Techniques Used: Expressing, Western Blot, Control, Fluorescence, Permeability, Microscopy, Imaging

    Acetate reverses chitosan-mediated repair of the intestinal barrier, increased inflammation in the colon, plasma, and SN, and promotes microglia activation in an MPTP-induced mouse model of PD. (A) Colon length ( n = 5/group). (B) ZO-1 and occludin expression, as assessed by western blot ( n = 3/group). All target proteins were normalized to the reference protein GAPDH. Compared with the chitosan group, acetate supplementation reduced ZO-1 and occludin expression levels. (C) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The immunofluorescence results were consistent with the western blot results. Scale bars: 10 μm. (D) The relative mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue were measured by QPCR ( n = 3/group). Compared with the chitosan group, acetate supplementation resulted in an increase in IL-1β, IL-6, IL-10, TNF-α, and iNOS expression levels in the colon. The data shown in B-D were normalized to the control group. (E) The expression levels of inflammatory cytokines, including IL-1β, IL-6, IL-10, and TNF-α, in mouse plasma were measured by ELISA ( n = 5/group). Compared with the chitosan group, IL-1β and TNF-α levels were significantly increased in the plasma of the acetate group, while IL-10 expression was significantly decreased. (F) The mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS (normalized to the control group) in mouse SN tissue were determined via QPCR ( n = 3/group). Treatment with acetate enhanced TNF-α expression and decreased IL-6 and IL-10 expression in the SN. (G) Representative images of immunofluorescence staining for Iba1 (green, Alexa Fluor 488) and TH (red, Alexa Fluor 594) in the SN ( n = 3/group). The chitosan group exhibited fewer microglia than the MPTP group, while the chitosan + acetate group exhibited more microglia than the chitosan-only group. Scale bars: 50 μm. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test [A–C, G] or unpaired t -test [D–F]). DAPI: 4′,6-Diamidino-2-phenylindole; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Iba1: ionized calcium-binding adapter molecule 1; IL-1β: interleukin-1 beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; n.s.: no significance; NaA: sodium acetate; PD: Parkinson’s disease; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.
    Figure Legend Snippet: Acetate reverses chitosan-mediated repair of the intestinal barrier, increased inflammation in the colon, plasma, and SN, and promotes microglia activation in an MPTP-induced mouse model of PD. (A) Colon length ( n = 5/group). (B) ZO-1 and occludin expression, as assessed by western blot ( n = 3/group). All target proteins were normalized to the reference protein GAPDH. Compared with the chitosan group, acetate supplementation reduced ZO-1 and occludin expression levels. (C) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The immunofluorescence results were consistent with the western blot results. Scale bars: 10 μm. (D) The relative mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue were measured by QPCR ( n = 3/group). Compared with the chitosan group, acetate supplementation resulted in an increase in IL-1β, IL-6, IL-10, TNF-α, and iNOS expression levels in the colon. The data shown in B-D were normalized to the control group. (E) The expression levels of inflammatory cytokines, including IL-1β, IL-6, IL-10, and TNF-α, in mouse plasma were measured by ELISA ( n = 5/group). Compared with the chitosan group, IL-1β and TNF-α levels were significantly increased in the plasma of the acetate group, while IL-10 expression was significantly decreased. (F) The mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS (normalized to the control group) in mouse SN tissue were determined via QPCR ( n = 3/group). Treatment with acetate enhanced TNF-α expression and decreased IL-6 and IL-10 expression in the SN. (G) Representative images of immunofluorescence staining for Iba1 (green, Alexa Fluor 488) and TH (red, Alexa Fluor 594) in the SN ( n = 3/group). The chitosan group exhibited fewer microglia than the MPTP group, while the chitosan + acetate group exhibited more microglia than the chitosan-only group. Scale bars: 50 μm. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test [A–C, G] or unpaired t -test [D–F]). DAPI: 4′,6-Diamidino-2-phenylindole; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Iba1: ionized calcium-binding adapter molecule 1; IL-1β: interleukin-1 beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; n.s.: no significance; NaA: sodium acetate; PD: Parkinson’s disease; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Techniques Used: Clinical Proteomics, Activation Assay, Expressing, Western Blot, Immunofluorescence, Staining, Control, Enzyme-linked Immunosorbent Assay, Binding Assay, Real-time Polymerase Chain Reaction

    Chitosan may reduce acetate levels, thereby activating the PPARD-AMPK signaling pathway, which promotes repair of the intestinal barrier and reduces neuroinflammation in an MPTP-induced mouse model of PD. (A, B) Western blot analysis of p-AMPK, AMPK, and PPARD levels in mouse colon tissue ( n = 3/group). Treatment with acetate significantly increased p-AMPK and PPARD expression. (C) Treatment with a PPARD antagonist significantly decreased mouse body weight ( n = 6/group). (D) There were no significant differences in fall latency among the groups in the rotarod test, which was used to assess motor dysfunction ( n = 6/group). (E–G) PPARD antagonist treatment significantly decreased PPARD, TH, ZO-1, and occludin expression, as determined by western blot ( n = 3/group). (H) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The PPARD antagonist treatment group exhibited markedly reduced ZO-1 and occludin mRNA expression levels in colon tissue. Scale bars: 10 μm. (I) QPCR was used to measure the mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue ( n = 3/group). Treatment with the PPARD antagonist increased IL-6 and TNF-α mRNA levels, while IL-8 and iNOS levels were reduced. (J) ELISA was used to detect IL-1β, IL-6, IL-10, and TNF-α expression levels in mouse plasma ( n = 5/group). IL-1β, IL-6, and TNF-α expression levels were significantly increased in the PPARD antagonist treatment group. (K) QPCR was used to measure mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in the SN ( n = 3/group). Treatment with the PPARD antagonist significantly increased the mRNA levels of IL-1β, IL-6, and IL-8. (L) Treatment with the PPARD antagonist reduced p-AMPK, but not AMPK, expression ( n = 3/group). GAPDH was used as the internal reference. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test (A, B) or unpaired t -test (C–L)). AMPK: Adenosine 5′-monophosphate-activated protein kinase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-1β: interleukin-1 Beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; n.s.: not significant; NaA: sodium acetate; p-AMPK: phosphorylation adenosine 5′-monophosphate-activated protein kinase; PD: Parkinson’s disease; PPARD: peroxisome proliferator-activated receptor delta; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.
    Figure Legend Snippet: Chitosan may reduce acetate levels, thereby activating the PPARD-AMPK signaling pathway, which promotes repair of the intestinal barrier and reduces neuroinflammation in an MPTP-induced mouse model of PD. (A, B) Western blot analysis of p-AMPK, AMPK, and PPARD levels in mouse colon tissue ( n = 3/group). Treatment with acetate significantly increased p-AMPK and PPARD expression. (C) Treatment with a PPARD antagonist significantly decreased mouse body weight ( n = 6/group). (D) There were no significant differences in fall latency among the groups in the rotarod test, which was used to assess motor dysfunction ( n = 6/group). (E–G) PPARD antagonist treatment significantly decreased PPARD, TH, ZO-1, and occludin expression, as determined by western blot ( n = 3/group). (H) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The PPARD antagonist treatment group exhibited markedly reduced ZO-1 and occludin mRNA expression levels in colon tissue. Scale bars: 10 μm. (I) QPCR was used to measure the mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue ( n = 3/group). Treatment with the PPARD antagonist increased IL-6 and TNF-α mRNA levels, while IL-8 and iNOS levels were reduced. (J) ELISA was used to detect IL-1β, IL-6, IL-10, and TNF-α expression levels in mouse plasma ( n = 5/group). IL-1β, IL-6, and TNF-α expression levels were significantly increased in the PPARD antagonist treatment group. (K) QPCR was used to measure mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in the SN ( n = 3/group). Treatment with the PPARD antagonist significantly increased the mRNA levels of IL-1β, IL-6, and IL-8. (L) Treatment with the PPARD antagonist reduced p-AMPK, but not AMPK, expression ( n = 3/group). GAPDH was used as the internal reference. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test (A, B) or unpaired t -test (C–L)). AMPK: Adenosine 5′-monophosphate-activated protein kinase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-1β: interleukin-1 Beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; n.s.: not significant; NaA: sodium acetate; p-AMPK: phosphorylation adenosine 5′-monophosphate-activated protein kinase; PD: Parkinson’s disease; PPARD: peroxisome proliferator-activated receptor delta; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Techniques Used: Western Blot, Expressing, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Phospho-proteomics, Real-time Polymerase Chain Reaction



    Similar Products

    rabbit anti occludin antibody  (Bioss)
    95
    Bioss rabbit anti occludin antibody
    Rabbit Anti Occludin Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti occludin antibody/product/Bioss
    Average 95 stars, based on 1 article reviews
    rabbit anti occludin antibody - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti occludin  (Sino Biological)
    93
    Sino Biological rabbit polyclonal anti occludin
    Rabbit Polyclonal Anti Occludin, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti occludin/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal anti occludin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    rabbit anti occludin polyclonal antibody  (Proteintech)
    96
    Proteintech rabbit anti occludin polyclonal antibody
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Anti Occludin Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti occludin polyclonal antibody/product/Proteintech
    Average 96 stars, based on 1 article reviews
    rabbit anti occludin polyclonal antibody - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    rabbit occludin polyclonal antibody  (Proteintech)
    96
    Proteintech rabbit occludin polyclonal antibody
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Occludin Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit occludin polyclonal antibody/product/Proteintech
    Average 96 stars, based on 1 article reviews
    rabbit occludin polyclonal antibody - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    rabbit anti occludin polyclonal pab  (Proteintech)
    96
    Proteintech rabbit anti occludin polyclonal pab
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Anti Occludin Polyclonal Pab, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti occludin polyclonal pab/product/Proteintech
    Average 96 stars, based on 1 article reviews
    rabbit anti occludin polyclonal pab - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti occludin  (Bioss)
    94
    Bioss rabbit polyclonal anti occludin
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Polyclonal Anti Occludin, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti occludin/product/Bioss
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal anti occludin - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    rabbit anti occludin  (Bioss)
    95
    Bioss rabbit anti occludin
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Rabbit Anti Occludin, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti occludin/product/Bioss
    Average 95 stars, based on 1 article reviews
    rabbit anti occludin - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    occludin  (Cusabio)
    92
    Cusabio occludin
    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and <t>occludin</t> expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.
    Occludin, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/occludin/product/Cusabio
    Average 92 stars, based on 1 article reviews
    occludin - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and occludin expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.

    Journal: Neural Regeneration Research

    Article Title: Chitosan alleviates symptoms of Parkinson’s disease by reducing acetate levels, which decreases inflammation and promotes repair of the intestinal barrier and blood–brain barrier

    doi: 10.4103/NRR.NRR-D-23-01511

    Figure Lengend Snippet: Chitosan treatment repairs damaged intestinal and blood–brain barriers in an MPTP-induced mouse model of PD. (A) Chitosan administration significantly increased ZO-1 and occludin expression levels, as detected by western blot. GAPDH was used as a loading control. (B) Chitosan treatment significantly increased the fluorescence intensity of ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue compared with the MPTP-induced PD group, and the fluorescence intensities of ZO-1 and occludin in PD group were lower than those in the control group. Scale bars: 10 μm. (C) Compared with MPTP-induced PD mice, chitosan treatment significantly decreased serum FITC-dextran levels, which are a measure of intestinal barrier integrity. (D) EB was used to monitor BBB permeability, and results were normalized to the control group. Chitosan treatment significantly reduced BBB damage. (E) EB measured by fluorescence microscopy imaging. Chitosan significantly restored BBB compared with MPTP-induced PD mice. Scale bars: 500 μm (upper) and 50 μm (lower). (F) EB of brain in mice measured by microplate reader. Chitosan treatment significantly decreased EB content compared with MPTP mice. All data are presented as the mean ± SD ( n = 3/group). * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test). BBB: Blood–brain barrier; DAPI: 4′,6-diamidino-2-phenylindole; EB: Evans blue; FITC-Dextran: Fluorescein isothiocyanate dextran; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD: Parkinson’s disease; ZO-1: Zonula occludens-1.

    Article Snippet: The primary antibodies used were as follows: rabbit anti-glyceraldehyde-3-phosphate dehydrogenase polyclonal antibody (GAPDH; 1:10,000, Proteintech, Wuhan, Hubei, China, Cat# 10494-1-AP, RRID: AB_2263076), rabbit anti-TH polyclonal antibody (1:5000, Proteintech, Cat# 25859-1-AP, RRID: AB_2716568), rabbit anti-zonula occludens-1 polyclonal antibody (ZO-1; 1:5000, Proteintech, Cat# 21773-1-AP, RRID: AB_10733242), rabbit anti-occludin polyclonal antibody (1:15,000, Proteintech, Cat# 27260-1-AP, RRID: AB_2880820), rabbit anti-AMPKα polyclonal antibody (1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA, Cat# 2532, RRID: AB_330331), rabbit anti-phospho-AMPKα monoclonal antibody (1:1000, Cell Signaling Technology, Cat# 2535, RRID: AB_331250), and rabbit anti-PPARD polyclonal antibody (1:1000, Abcam, Cambridge, UK, Cat# ab23673, RRID: AB_2165902).

    Techniques: Expressing, Western Blot, Control, Fluorescence, Permeability, Microscopy, Imaging

    Acetate reverses chitosan-mediated repair of the intestinal barrier, increased inflammation in the colon, plasma, and SN, and promotes microglia activation in an MPTP-induced mouse model of PD. (A) Colon length ( n = 5/group). (B) ZO-1 and occludin expression, as assessed by western blot ( n = 3/group). All target proteins were normalized to the reference protein GAPDH. Compared with the chitosan group, acetate supplementation reduced ZO-1 and occludin expression levels. (C) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The immunofluorescence results were consistent with the western blot results. Scale bars: 10 μm. (D) The relative mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue were measured by QPCR ( n = 3/group). Compared with the chitosan group, acetate supplementation resulted in an increase in IL-1β, IL-6, IL-10, TNF-α, and iNOS expression levels in the colon. The data shown in B-D were normalized to the control group. (E) The expression levels of inflammatory cytokines, including IL-1β, IL-6, IL-10, and TNF-α, in mouse plasma were measured by ELISA ( n = 5/group). Compared with the chitosan group, IL-1β and TNF-α levels were significantly increased in the plasma of the acetate group, while IL-10 expression was significantly decreased. (F) The mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS (normalized to the control group) in mouse SN tissue were determined via QPCR ( n = 3/group). Treatment with acetate enhanced TNF-α expression and decreased IL-6 and IL-10 expression in the SN. (G) Representative images of immunofluorescence staining for Iba1 (green, Alexa Fluor 488) and TH (red, Alexa Fluor 594) in the SN ( n = 3/group). The chitosan group exhibited fewer microglia than the MPTP group, while the chitosan + acetate group exhibited more microglia than the chitosan-only group. Scale bars: 50 μm. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test [A–C, G] or unpaired t -test [D–F]). DAPI: 4′,6-Diamidino-2-phenylindole; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Iba1: ionized calcium-binding adapter molecule 1; IL-1β: interleukin-1 beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; n.s.: no significance; NaA: sodium acetate; PD: Parkinson’s disease; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Journal: Neural Regeneration Research

    Article Title: Chitosan alleviates symptoms of Parkinson’s disease by reducing acetate levels, which decreases inflammation and promotes repair of the intestinal barrier and blood–brain barrier

    doi: 10.4103/NRR.NRR-D-23-01511

    Figure Lengend Snippet: Acetate reverses chitosan-mediated repair of the intestinal barrier, increased inflammation in the colon, plasma, and SN, and promotes microglia activation in an MPTP-induced mouse model of PD. (A) Colon length ( n = 5/group). (B) ZO-1 and occludin expression, as assessed by western blot ( n = 3/group). All target proteins were normalized to the reference protein GAPDH. Compared with the chitosan group, acetate supplementation reduced ZO-1 and occludin expression levels. (C) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The immunofluorescence results were consistent with the western blot results. Scale bars: 10 μm. (D) The relative mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue were measured by QPCR ( n = 3/group). Compared with the chitosan group, acetate supplementation resulted in an increase in IL-1β, IL-6, IL-10, TNF-α, and iNOS expression levels in the colon. The data shown in B-D were normalized to the control group. (E) The expression levels of inflammatory cytokines, including IL-1β, IL-6, IL-10, and TNF-α, in mouse plasma were measured by ELISA ( n = 5/group). Compared with the chitosan group, IL-1β and TNF-α levels were significantly increased in the plasma of the acetate group, while IL-10 expression was significantly decreased. (F) The mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS (normalized to the control group) in mouse SN tissue were determined via QPCR ( n = 3/group). Treatment with acetate enhanced TNF-α expression and decreased IL-6 and IL-10 expression in the SN. (G) Representative images of immunofluorescence staining for Iba1 (green, Alexa Fluor 488) and TH (red, Alexa Fluor 594) in the SN ( n = 3/group). The chitosan group exhibited fewer microglia than the MPTP group, while the chitosan + acetate group exhibited more microglia than the chitosan-only group. Scale bars: 50 μm. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test [A–C, G] or unpaired t -test [D–F]). DAPI: 4′,6-Diamidino-2-phenylindole; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Iba1: ionized calcium-binding adapter molecule 1; IL-1β: interleukin-1 beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; n.s.: no significance; NaA: sodium acetate; PD: Parkinson’s disease; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Article Snippet: The primary antibodies used were as follows: rabbit anti-glyceraldehyde-3-phosphate dehydrogenase polyclonal antibody (GAPDH; 1:10,000, Proteintech, Wuhan, Hubei, China, Cat# 10494-1-AP, RRID: AB_2263076), rabbit anti-TH polyclonal antibody (1:5000, Proteintech, Cat# 25859-1-AP, RRID: AB_2716568), rabbit anti-zonula occludens-1 polyclonal antibody (ZO-1; 1:5000, Proteintech, Cat# 21773-1-AP, RRID: AB_10733242), rabbit anti-occludin polyclonal antibody (1:15,000, Proteintech, Cat# 27260-1-AP, RRID: AB_2880820), rabbit anti-AMPKα polyclonal antibody (1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA, Cat# 2532, RRID: AB_330331), rabbit anti-phospho-AMPKα monoclonal antibody (1:1000, Cell Signaling Technology, Cat# 2535, RRID: AB_331250), and rabbit anti-PPARD polyclonal antibody (1:1000, Abcam, Cambridge, UK, Cat# ab23673, RRID: AB_2165902).

    Techniques: Clinical Proteomics, Activation Assay, Expressing, Western Blot, Immunofluorescence, Staining, Control, Enzyme-linked Immunosorbent Assay, Binding Assay, Real-time Polymerase Chain Reaction

    Chitosan may reduce acetate levels, thereby activating the PPARD-AMPK signaling pathway, which promotes repair of the intestinal barrier and reduces neuroinflammation in an MPTP-induced mouse model of PD. (A, B) Western blot analysis of p-AMPK, AMPK, and PPARD levels in mouse colon tissue ( n = 3/group). Treatment with acetate significantly increased p-AMPK and PPARD expression. (C) Treatment with a PPARD antagonist significantly decreased mouse body weight ( n = 6/group). (D) There were no significant differences in fall latency among the groups in the rotarod test, which was used to assess motor dysfunction ( n = 6/group). (E–G) PPARD antagonist treatment significantly decreased PPARD, TH, ZO-1, and occludin expression, as determined by western blot ( n = 3/group). (H) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The PPARD antagonist treatment group exhibited markedly reduced ZO-1 and occludin mRNA expression levels in colon tissue. Scale bars: 10 μm. (I) QPCR was used to measure the mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue ( n = 3/group). Treatment with the PPARD antagonist increased IL-6 and TNF-α mRNA levels, while IL-8 and iNOS levels were reduced. (J) ELISA was used to detect IL-1β, IL-6, IL-10, and TNF-α expression levels in mouse plasma ( n = 5/group). IL-1β, IL-6, and TNF-α expression levels were significantly increased in the PPARD antagonist treatment group. (K) QPCR was used to measure mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in the SN ( n = 3/group). Treatment with the PPARD antagonist significantly increased the mRNA levels of IL-1β, IL-6, and IL-8. (L) Treatment with the PPARD antagonist reduced p-AMPK, but not AMPK, expression ( n = 3/group). GAPDH was used as the internal reference. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test (A, B) or unpaired t -test (C–L)). AMPK: Adenosine 5′-monophosphate-activated protein kinase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-1β: interleukin-1 Beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; n.s.: not significant; NaA: sodium acetate; p-AMPK: phosphorylation adenosine 5′-monophosphate-activated protein kinase; PD: Parkinson’s disease; PPARD: peroxisome proliferator-activated receptor delta; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Journal: Neural Regeneration Research

    Article Title: Chitosan alleviates symptoms of Parkinson’s disease by reducing acetate levels, which decreases inflammation and promotes repair of the intestinal barrier and blood–brain barrier

    doi: 10.4103/NRR.NRR-D-23-01511

    Figure Lengend Snippet: Chitosan may reduce acetate levels, thereby activating the PPARD-AMPK signaling pathway, which promotes repair of the intestinal barrier and reduces neuroinflammation in an MPTP-induced mouse model of PD. (A, B) Western blot analysis of p-AMPK, AMPK, and PPARD levels in mouse colon tissue ( n = 3/group). Treatment with acetate significantly increased p-AMPK and PPARD expression. (C) Treatment with a PPARD antagonist significantly decreased mouse body weight ( n = 6/group). (D) There were no significant differences in fall latency among the groups in the rotarod test, which was used to assess motor dysfunction ( n = 6/group). (E–G) PPARD antagonist treatment significantly decreased PPARD, TH, ZO-1, and occludin expression, as determined by western blot ( n = 3/group). (H) Immunofluorescence staining for ZO-1 (green, Alexa Fluor 488) and occludin (red, Alexa Fluor 594) in mouse colon tissue ( n = 3/group). The PPARD antagonist treatment group exhibited markedly reduced ZO-1 and occludin mRNA expression levels in colon tissue. Scale bars: 10 μm. (I) QPCR was used to measure the mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in mouse colon tissue ( n = 3/group). Treatment with the PPARD antagonist increased IL-6 and TNF-α mRNA levels, while IL-8 and iNOS levels were reduced. (J) ELISA was used to detect IL-1β, IL-6, IL-10, and TNF-α expression levels in mouse plasma ( n = 5/group). IL-1β, IL-6, and TNF-α expression levels were significantly increased in the PPARD antagonist treatment group. (K) QPCR was used to measure mRNA levels of IL-1β, IL-6, IL-8, IL-10, TNF-α, and iNOS in the SN ( n = 3/group). Treatment with the PPARD antagonist significantly increased the mRNA levels of IL-1β, IL-6, and IL-8. (L) Treatment with the PPARD antagonist reduced p-AMPK, but not AMPK, expression ( n = 3/group). GAPDH was used as the internal reference. All data are presented as the mean ± SD. All experiments were repeated at least three times. * P < 0.05 (one-way analysis of variance followed by Tukey’s multiple comparisons test (A, B) or unpaired t -test (C–L)). AMPK: Adenosine 5′-monophosphate-activated protein kinase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-1β: interleukin-1 Beta; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; iNOS: inductible nitric oxide synthase; n.s.: not significant; NaA: sodium acetate; p-AMPK: phosphorylation adenosine 5′-monophosphate-activated protein kinase; PD: Parkinson’s disease; PPARD: peroxisome proliferator-activated receptor delta; QPCR: quantitative polymerase chain reaction; SN: substantia nigra; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; ZO-1: Zonula occludens-1.

    Article Snippet: The primary antibodies used were as follows: rabbit anti-glyceraldehyde-3-phosphate dehydrogenase polyclonal antibody (GAPDH; 1:10,000, Proteintech, Wuhan, Hubei, China, Cat# 10494-1-AP, RRID: AB_2263076), rabbit anti-TH polyclonal antibody (1:5000, Proteintech, Cat# 25859-1-AP, RRID: AB_2716568), rabbit anti-zonula occludens-1 polyclonal antibody (ZO-1; 1:5000, Proteintech, Cat# 21773-1-AP, RRID: AB_10733242), rabbit anti-occludin polyclonal antibody (1:15,000, Proteintech, Cat# 27260-1-AP, RRID: AB_2880820), rabbit anti-AMPKα polyclonal antibody (1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA, Cat# 2532, RRID: AB_330331), rabbit anti-phospho-AMPKα monoclonal antibody (1:1000, Cell Signaling Technology, Cat# 2535, RRID: AB_331250), and rabbit anti-PPARD polyclonal antibody (1:1000, Abcam, Cambridge, UK, Cat# ab23673, RRID: AB_2165902).

    Techniques: Western Blot, Expressing, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Phospho-proteomics, Real-time Polymerase Chain Reaction